Sagimet Biosciences Inc
sagimet.comSagimet Biosciences Inc (NASDAQ: SGMT) is a clinical-stage biopharmaceutical company developing small-molecule drug candidates targeting fatty acid synthesis pathways. The company generates no product revenue and funds operations entirely through existing cash, cash equivalents, and marketable securities while spending on clinical development and manufacturing. As of the 10-K filed March 11, 2026, Sagimet's primary asset is denifanstat, a fatty acid synthase (FASN) inhibitor in clinical development for metabolic dysfunction-associated steatohepatitis (MASH), with a Phase 3 trial underway and a Phase 1 pharmacokinetic trial evaluating the combination of denifanstat and resmetirom. A second candidate, TVB-3567, was also in clinical development as of the same filing. Net cash used in operating activities was $45.7 million for the year ended December 31, 2025, compared to $42.4 million for the year ended December 31, 2024, reflecting ongoing trial costs and public-company infrastructure spend.
Products & Services
Denifanstat: a FASN inhibitor in Phase 3 development for MASH and in a Phase 1 pharmacokinetic trial in combination with resmetirom. TVB-3567: a second drug candidate in clinical development. Both are small-molecule compounds targeting fatty acid synthesis (per 10-K filed 2026-03-11).
Revenue Model
Pre-revenue clinical-stage company. No product sales as of the 10-K filed March 11, 2026. Operations are funded by cash reserves and proceeds from marketable securities. Other income consists primarily of interest earned on cash, cash equivalents, and marketable securities.
Customers & Markets
No commercial customers as of the filing date. Target end market is patients with MASH (metabolic dysfunction-associated steatohepatitis). Future customers would include payors, hospitals, and specialty pharmacies upon any regulatory approval.
Geographic Exposure
Primarily U.S.-based operations. Regulatory filings reference FDA oversight as primary pathway. Filing also references EU, UK (MHRA), and other international regulatory regimes as potential future markets, though no commercial operations outside the U.S. are described (per 10-K filed 2026-03-11).
Financial Snapshot
Loading...
